SI2605652T1 - Diketones and hydroxyketones as catenin signaling pathways - Google Patents

Diketones and hydroxyketones as catenin signaling pathways Download PDF

Info

Publication number
SI2605652T1
SI2605652T1 SI201131411T SI201131411T SI2605652T1 SI 2605652 T1 SI2605652 T1 SI 2605652T1 SI 201131411 T SI201131411 T SI 201131411T SI 201131411 T SI201131411 T SI 201131411T SI 2605652 T1 SI2605652 T1 SI 2605652T1
Authority
SI
Slovenia
Prior art keywords
compound
disease
diseases
formula
substituted
Prior art date
Application number
SI201131411T
Other languages
English (en)
Slovenian (sl)
Inventor
Sunil Kumar Kc
David Mark Wallace
John Hood
Charlene F. Barroga
Original Assignee
Samumed, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samumed, Llc filed Critical Samumed, Llc
Publication of SI2605652T1 publication Critical patent/SI2605652T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/782—Ketones containing a keto group bound to a six-membered aromatic ring polycyclic
    • C07C49/784—Ketones containing a keto group bound to a six-membered aromatic ring polycyclic with all keto groups bound to a non-condensed ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
SI201131411T 2010-08-18 2011-08-17 Diketones and hydroxyketones as catenin signaling pathways SI2605652T1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US37468710P 2010-08-18 2010-08-18
US201061427974P 2010-12-29 2010-12-29
EP11818727.7A EP2605652B1 (en) 2010-08-18 2011-08-17 Diketones and hydroxyketones as catenin signaling pathway activators
PCT/US2011/048086 WO2012024404A1 (en) 2010-08-18 2011-08-17 Diketones and hydroxyketones as catenin signaling pathway activators

Publications (1)

Publication Number Publication Date
SI2605652T1 true SI2605652T1 (en) 2018-04-30

Family

ID=45594555

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201131411T SI2605652T1 (en) 2010-08-18 2011-08-17 Diketones and hydroxyketones as catenin signaling pathways
SI201131978T SI3311666T1 (sl) 2010-08-18 2011-08-17 Diketoni in hidroksiketoni, kot aktivatorji signalne poti katenina

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201131978T SI3311666T1 (sl) 2010-08-18 2011-08-17 Diketoni in hidroksiketoni, kot aktivatorji signalne poti katenina

Country Status (22)

Country Link
US (9) US8609717B2 (enExample)
EP (3) EP2605652B1 (enExample)
JP (3) JP6086864B2 (enExample)
CN (2) CN104672202B (enExample)
AU (1) AU2011291989B2 (enExample)
BR (1) BR112013003631B1 (enExample)
CA (1) CA2807419C (enExample)
CY (2) CY1120061T1 (enExample)
DK (2) DK3311666T3 (enExample)
ES (2) ES2879314T3 (enExample)
HR (2) HRP20180196T1 (enExample)
HU (2) HUE036240T2 (enExample)
LT (2) LT3311666T (enExample)
MX (2) MX340997B (enExample)
NO (1) NO2605652T3 (enExample)
PL (2) PL3311666T3 (enExample)
PT (2) PT2605652T (enExample)
RS (2) RS56855B1 (enExample)
RU (2) RU2016124136A (enExample)
SI (2) SI2605652T1 (enExample)
SM (2) SMT201800065T1 (enExample)
WO (1) WO2012024404A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009158393A1 (en) 2008-06-25 2009-12-30 Envivo Pharmaceuticals, Inc. 1, 2 disubstituted heterocyclic compounds
EP2617420B1 (en) 2009-05-07 2015-09-23 Forum Pharmaceuticals Inc. Phenoxymethyl heterocyclic compounds
DK2987487T3 (da) 2009-08-10 2020-12-07 Samumed Llc Indazolinhibitorer af wnt-signalvejen og terapeutiske anvendelser deraf
SMT201800065T1 (it) * 2010-08-18 2018-03-08 Samumed Llc Dichetoni e idrossichetoni come attivatori della via di segnalazione della catechina
US20140037599A1 (en) * 2012-08-03 2014-02-06 The Trustees Of The University Of Pennsylvania Compositions and Methods of Treating T Cell Deficiency
EP2968249B1 (en) * 2013-02-22 2018-11-14 Samumed, LLC Gamma-diketones as wnt/beta -catenin signaling pathway activators
ES2762559T3 (es) * 2014-08-20 2020-05-25 Samumed Llc Gamma-dicetonas para tratamiento y prevención de envejecimiento de la piel y arrugas
IL319729A (en) * 2016-07-19 2025-05-01 Accellta Ltd Medium for growing pluripotent stem cells in suspension
BR112019013388A2 (pt) 2016-12-30 2020-03-03 Frequency Therapeutics, Inc. Compostos de 1h-pirrol-2,5-diona e métodos de uso dos mesmos para induzir a autorrenovação de células de suporte tronco/progenitoras
WO2020037323A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating jag-1
EP3837351A1 (en) 2018-08-17 2021-06-23 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
US12398126B2 (en) * 2019-06-06 2025-08-26 Fermenta Biotech Limited Process to synthesize 5-(3pyridyl)-2,2′-bithiophene(sensitizer)

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3040054A (en) 1960-08-03 1962-06-19 Olin Mathieson 2, 2'-(1, 4-diaminotetramethylene) bis(4-thiazolecarboxylic acid), salts and process
US3855675A (en) 1971-05-25 1974-12-24 Squibb & Sons Inc 1-(2-furanylmethyl)-1h-pyrazolo(3,4-b)pyridine-5-methanones
US4014889A (en) * 1972-12-20 1977-03-29 Bayer Aktiengesellschaft Process for preparing ketones
DE2262343A1 (de) * 1972-12-20 1974-06-27 Bayer Ag Verfahren zur herstellung von ketonen
US4032526A (en) 1975-10-02 1977-06-28 American Cyanamid Company 1,2-dimethyl-3 or 5-piperazinyl-pyrazolium salts
US4164559A (en) 1977-09-21 1979-08-14 Cornell Research Foundation, Inc. Collagen drug delivery device
DE2808070A1 (de) 1978-02-24 1979-08-30 Bayer Ag Verfahren zur herstellung von 4-pyridon-3-carbonsaeuren und/oder deren derivaten
US4761471A (en) 1980-08-04 1988-08-02 The Regents Of The University Of California Bone morphogenetic protein composition
US4474752A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
DE3331692A1 (de) 1983-09-02 1985-03-28 Basf Ag, 6700 Ludwigshafen 3-phenyl-4-methoxycarbonylpyrazole, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses
EP0230110A1 (en) 1985-11-30 1987-07-29 FISONS plc Pharmacologically active pyrrole and pyrazole derivatives
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
EP0290442A4 (en) 1986-11-19 1990-07-03 Chemex Pharmaceuticals Inc MEDICINAL PREPARATIONS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS.
NZ227287A (en) 1987-12-21 1992-01-29 Merck & Co Inc 2,5-diaryl tetrahydrofurans and medicaments
AU626881B2 (en) 1988-07-14 1992-08-13 F. Hoffmann-La Roche Ag Benzofused heterocyclics used as pharmaceuticals
IL91418A (en) 1988-09-01 1997-11-20 Rhone Poulenc Agrochimie (hetero) cyclic amide derivatives, process for their preparation and fungicidal compositions containing them
EP0365089A3 (en) 1988-10-18 1991-06-05 Merck & Co. Inc. 2-aryl-5(3-methoxy-5-(hydroxypropylsulfonyl)-4-propoxyphenyl) tetrahydrothiophen and analogs
EP0429570B1 (en) 1989-03-28 1998-01-14 Genetics Institute, Inc. Osteoinductive compositions
ATE124394T1 (de) * 1990-04-27 1995-07-15 Duphar Int Res Verfahren zur photochemischen isomerisierung von organischen verbindungen unter dem einfluss eines photosensibilisators.
DE4104931A1 (de) 1991-02-18 1992-08-20 Hoechst Ag Verfahren zur herstellung substituierter indene
JPH05170764A (ja) * 1991-12-24 1993-07-09 Sumitomo Pharmaceut Co Ltd 新規なヒドロキシカルコン誘導体
GB9203806D0 (en) 1992-02-21 1992-04-08 Unilever Plc Sunscreen agents
DK57892D0 (da) 1992-05-01 1992-05-01 Nkt Res Center As Fremgangsmaade til fremstilling af 1,4-bis-aryl-butan-1,4-dioner og poly(arylen-butan-1,4-dioner)
ES2157345T3 (es) * 1994-10-07 2001-08-16 Meiji Seika Co Compuestos de gamma-dicetona con actividad inhibidora contra la agregacion de plaquetas.
AU1726695A (en) 1995-01-13 1996-07-31 Board Of Regents, The University Of Texas System Turcasarins, novel expanded porphyrins, and uses thereof
US5668148A (en) 1995-04-20 1997-09-16 Merck & Co., Inc. Alpha1a adrenergic receptor antagonists
US5585118A (en) 1995-06-02 1996-12-17 Brigham And Women's Hospital Choline in the treatment of bipolar disorder
US5668165A (en) 1995-06-07 1997-09-16 Scriptgen Pharmaceuticals, Inc. Small molecule inhibition of RNA/ligand binding
JP3964478B2 (ja) * 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
IL125820A0 (en) 1996-02-19 1999-04-11 Japan Tobacco Inc Therapeutic agent for diabetes and a pharmaceutical composition containing the same
ES2205240T3 (es) 1996-06-03 2004-05-01 Purdue Research Foundation Agentes anti-tumorales de selenofenos.
US6620804B2 (en) 1996-06-03 2003-09-16 Purdue Research Foundation Selenophene anti-tumor agents
US6440102B1 (en) 1998-07-23 2002-08-27 Durect Corporation Fluid transfer and diagnostic system for treating the inner ear
KR20010071975A (ko) * 1998-08-11 2001-07-31 해슬러 요세 살선충성 피라졸
EP1127054A4 (en) 1998-10-29 2006-11-02 Bristol Myers Squibb Co INHIBITORS OF IMPDH ENZYME
DE19853299C2 (de) 1998-11-19 2003-04-03 Thomas Lenarz Katheter zur Applikation von Medikamenten in Flüssigkeitsräumen des menschlichen Innenohrs
US6120484A (en) 1999-02-17 2000-09-19 Silverstein; Herbert Otological implant for delivery of medicament and method of using same
AU5880600A (en) * 1999-06-25 2001-01-31 Merck & Co., Inc. 1-(aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof
DE50013485D1 (de) 1999-07-09 2006-11-02 Forschungszentrum Juelich Gmbh Verfahren zur Reduktion von Ketogruppen enthaltende Verbindungen
HK1046682B (zh) 1999-07-13 2005-04-08 隆萨股份公司 2-氨基-4-(4-氟苯基)-6-烷基嘧啶-5-羧酸酯的制备方法
DE60019505T2 (de) * 1999-08-06 2005-09-15 Ciba Speciality Chemicals Holding Inc. Mikrobizide Wirksubstanzen
AUPQ288499A0 (en) 1999-09-16 1999-10-07 Biota Scientific Management Pty Ltd Antiviral agents
ATE316531T1 (de) 1999-10-07 2006-02-15 Lilly Co Eli Kondensierte dihydrochinolinon-derivate zur hemmung von mrp1
US6268375B1 (en) 1999-12-29 2001-07-31 Research Triangle Institute 10, 11-difluoromethylenedioxycamptothecin compounds with topoisomerase I inhibition
US6967023B1 (en) 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
JP2001294581A (ja) 2000-04-12 2001-10-23 Nippon Bayer Agrochem Co Ltd イソチアゾール誘導体
US6794362B1 (en) 2000-05-30 2004-09-21 Connective Tissue Imagineering Llc Asparagine containing elastin peptide analogs
KR100748294B1 (ko) 2000-07-05 2007-08-09 아스텔라스세이야쿠 가부시키가이샤 프로판-1,3-디온 유도체
DE10059749A1 (de) 2000-12-01 2002-06-20 Henkel Kgaa Fixierung von Wirkstoffen an fasrigen Materialien
JP4365094B2 (ja) * 2001-03-02 2009-11-18 メルク フロスト カナダ リミテツド カテプシンシステインプロテアーゼ阻害薬
US6949544B2 (en) 2001-03-29 2005-09-27 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
DE60232669D1 (de) 2001-04-30 2009-07-30 Vertex Pharma Inhibitoren von gsk-3 und kristallstrukturen von gsk-3beta-protein und -proteinkomplexen
US6987123B2 (en) * 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
WO2003016266A1 (fr) 2001-08-16 2003-02-27 Japan Tobacco Inc. Composes $g(b)-cetoamides et leur utilisation medicinale
US6648873B2 (en) 2001-09-21 2003-11-18 Durect Corp. Aural catheter system including anchor balloon and balloon inflation device
JPWO2003037316A1 (ja) * 2001-10-11 2005-02-17 株式会社カネカ ペルオキシソーム増殖剤応答性受容体リガンド剤及びその製造法
CN1155590C (zh) * 2002-04-12 2004-06-30 中国药科大学 具有抗肿瘤活性的色酮类化合物及其开环产物与制备方法
AU2003265395A1 (en) * 2002-08-14 2004-03-03 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
US20040266732A1 (en) 2002-09-20 2004-12-30 Jorge Galvez Therapeutic agents, methods, and treatments
FR2849598B1 (fr) 2003-01-07 2006-09-22 Merck Sante Sas Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete, par augmentation du nombre de cellules des ilots de langerhans
US20040224003A1 (en) 2003-02-07 2004-11-11 Schultz Robert K. Drug formulations for coating medical devices
ATE387435T1 (de) 2003-04-15 2008-03-15 Astrazeneca Ab Substituirte benzosulfonamide als potenzierungsmittel von glutamatrezeptoren
NZ545326A (en) 2003-07-17 2009-12-24 Plexxikon Inc PPAR active compounds
US7008953B2 (en) 2003-07-30 2006-03-07 Agouron Pharmaceuticals, Inc. 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US20060276536A1 (en) 2004-02-12 2006-12-07 Vander Jagt David L Cancer treatment using curcumin derivatives
US8841326B2 (en) 2004-02-12 2014-09-23 Stc.Unm Therapeutic curcumin derivatives
WO2005085227A1 (en) 2004-03-02 2005-09-15 Smithkline Beecham Corporation Inhibitors of akt activity
ZA200609924B (en) 2004-05-06 2008-12-31 Univ California Substituted enaminones, their derivatives and uses thereof
WO2005118556A1 (ja) 2004-06-04 2005-12-15 Astellas Pharma Inc. プロパン－１，３－ジオン誘導体又はその塩
DE102004029309A1 (de) 2004-06-17 2005-12-29 Bayer Cropscience Gmbh Pyridinylisoxazole und ihre Verwendung als Herbizide
US20080146555A1 (en) * 2004-06-18 2008-06-19 Gpc Biotech, Inc Uses of Kinase Inhibitors and Compositions Thereof
WO2006017896A1 (en) 2004-08-16 2006-02-23 The University Of Queensland Metabolism-modulating agents and uses therefor
FR2880802B1 (fr) 2005-01-14 2008-12-19 Sederma Soc Par Actions Simpli Composition cosmetique ou dermopharmaceutique contenant un extrait d'euglene
JP2008094720A (ja) 2005-01-20 2008-04-24 Astellas Pharma Inc キノロン誘導体のプロドラッグ又はその塩
JP2008537684A (ja) 2005-01-24 2008-09-25 ニューロシステック コーポレイション 内耳およびその他の組織へ治療薬および／またはその他の薬剤を送達するための装置および方法
RU2007124935A (ru) 2005-02-01 2009-03-10 Вайет (Us) АМИНОПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ β-СЕКТРЕТАЗЫ
CA2603185C (en) * 2005-03-31 2011-07-26 Astellas Pharma Inc. Propane-1,3-dione derivative or salt thereof
JP5050206B2 (ja) * 2005-06-27 2012-10-17 国立大学法人東北大学 ビス（アリールメチリデン）アセトン化合物、抗癌剤、発癌予防剤、Ｋｉ−Ｒａｓ、ＥｒｂＢ２、ｃ−Ｍｙｃ及びＣｙｃｌｉｎＤ１の発現抑制剤、β−カテニン分解剤並びにｐ５３の発現増強剤
DE102005031580A1 (de) * 2005-07-06 2007-01-11 Aicuris Gmbh & Co. Kg Substituierte Sulfolanylpyrazole und ihre Verwendung
CN101365446B (zh) 2005-07-29 2013-05-22 雷斯弗洛吉克斯公司 预防和治疗复杂疾病的药物组合物及其经由可植入医药装置的递送
WO2007051314A1 (en) 2005-11-07 2007-05-10 American Diagnostica Inc. Curcuminoid compounds for inhibiting plasminogen activator inhibitor-1
CA2629461C (en) 2005-11-10 2016-01-12 Anita Melikian Substituted quinolones and methods of use
WO2007103584A2 (en) 2006-03-09 2007-09-13 Nanovir, Llc Polyamides for treating human papilloma virus
KR20080109918A (ko) 2006-04-11 2008-12-17 버텍스 파마슈티칼스 인코포레이티드 전압 개폐 나트륨 채널의 억제제로서 유용한 조성물
JP2008007428A (ja) 2006-06-27 2008-01-17 Showa Denko Kk 皮膚外用シワ防止剤
JPWO2008020625A1 (ja) 2006-08-17 2010-01-07 国立大学法人金沢大学 ジベンゾイルメタン系化合物とそれを有効成分とする医薬組成物
EP2057981A4 (en) 2006-08-30 2014-01-22 Yakult Honsha Kk Anti-wrinkle agent
US7875603B2 (en) 2006-09-21 2011-01-25 Nova Southeastern University Specific inhibitors for vascular endothelial growth factor receptors
JP5207341B2 (ja) 2006-10-26 2013-06-12 独立行政法人産業技術総合研究所 炎症性サイトカイン産生抑制剤
JP5231829B2 (ja) * 2007-02-15 2013-07-10 石原産業株式会社 ピリジル−トリアゾロピリミジン誘導体又はその塩、それらを含有する有害生物防除剤並びにそれらの製造方法
WO2008118626A2 (en) 2007-03-08 2008-10-02 Burnham Institute For Medical Research Inhibitors of jnk and methods for identifying inhibitors of jnk
JP5309318B2 (ja) 2007-03-09 2013-10-09 国立大学法人 岡山大学 エステル、カルボン酸及びアミドの製造方法
KR101404398B1 (ko) 2007-06-20 2014-06-09 (주)뉴트리 주름개선 화장료 조성물
KR20100091170A (ko) 2007-11-02 2010-08-18 노파르티스 아게 저밀도-지단백질 수용체-관련 단백질 ６ (ｌｒｐ６)을 조정하기 위한 분자 및 방법
CA2704648A1 (en) 2007-11-05 2009-05-14 Novartis Ag Methods and compositions for measuring wnt activation and for treating wnt-related cancers
WO2009071997A2 (en) 2007-12-06 2009-06-11 Centre National De La Recherche Scientifique (C.N.R.S.) Iron and copper catalytic systems for cross-coupling reactions
JP2009179619A (ja) * 2008-02-01 2009-08-13 Toyo Ink Mfg Co Ltd 新規オキシムエステル化合物およびそれを含んでなるラジカル重合開始剤および重合性組成物
US20090232754A1 (en) * 2008-02-27 2009-09-17 Schering-Plough Healthcare Products, Inc. Enhanced photostability of suncare compositions containing avobenzone
CA2721371C (en) 2008-04-14 2016-07-12 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of the pleckstrin homology domain and methods for using same
KR101538822B1 (ko) 2008-05-08 2015-07-22 노바 사우쓰이스턴 유니버시티 혈관 내피 성장 인자 수용체에 대한 특이적 억제제
AU2009313491A1 (en) 2008-11-05 2011-06-30 University Of Southern California Small molecule modulators of epigenetic regulation and their therapeutic applications
WO2010075551A1 (en) * 2008-12-24 2010-07-01 Massachusetts Institute Of Technology Compositions of modulators of the wnt/beta-catenin pathway and benzamide and/or hydroxamic acid derivatives to treat bipolar disorder
JP5246715B2 (ja) 2009-01-27 2013-07-24 独立行政法人科学技術振興機構 蛋白質架橋阻害剤およびその用途
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
WO2011009826A2 (en) 2009-07-21 2011-01-27 ADAMED Sp.z o.o. Novel chalcone derivatives with cytotoxic activity
SMT201800065T1 (it) 2010-08-18 2018-03-08 Samumed Llc Dichetoni e idrossichetoni come attivatori della via di segnalazione della catechina
KR101784940B1 (ko) 2010-08-31 2017-10-12 (주)아모레퍼시픽 피부 탄력 개선용 화장료 조성물
WO2012106343A2 (en) 2011-02-01 2012-08-09 The Board Of Trustees Of The University Of Illinois Hdac inhibitors and therapeutic methods using the same
US8871748B2 (en) 2011-09-07 2014-10-28 Island Kinetics Inc. Retinal cyclodextrin acetals and hemiacetals for treating skin complexion disorder
US9668691B2 (en) 2011-09-22 2017-06-06 Lvmh Recherche Method to measure skin elasticity and firmness
WO2013113722A1 (en) 2012-01-30 2013-08-08 Universiteit Gent Anti-invasive compounds
US20130302381A1 (en) 2012-05-09 2013-11-14 Cook Medical Technologies Llc Implantable Medical Devices Including a Water-Insoluble Therapeutic Agent
US8865700B2 (en) 2012-12-20 2014-10-21 Avon Products, Inc. Collagen stimulators and their use in the treatment of skin
EP2968249B1 (en) 2013-02-22 2018-11-14 Samumed, LLC Gamma-diketones as wnt/beta -catenin signaling pathway activators
JP6464098B2 (ja) 2013-02-22 2019-02-06 ハー・ルンドベック・アクチエゼルスカベット ボルチオキセチンの製造方法
JP6145179B2 (ja) 2013-02-22 2017-06-07 ファイザー・インク ヤヌス関連キナーゼ（ＪＡＫ）の阻害剤としてのピロロ［２，３−ｄ］ピリミジン誘導体
KR20160037130A (ko) 2013-02-22 2016-04-05 스템센트알엑스 인코포레이티드 신규한 항체 접합체 및 이의 용도
ES2762559T3 (es) 2014-08-20 2020-05-25 Samumed Llc Gamma-dicetonas para tratamiento y prevención de envejecimiento de la piel y arrugas

Also Published As

Publication number Publication date
US9884053B2 (en) 2018-02-06
AU2011291989A1 (en) 2013-03-07
US20170246154A1 (en) 2017-08-31
CN103153053B (zh) 2015-02-18
HK1254638A1 (en) 2019-07-26
US20140005228A1 (en) 2014-01-02
JP6086864B2 (ja) 2017-03-01
RU2592694C2 (ru) 2016-07-27
EP3311666B8 (en) 2021-06-23
CN104672202A (zh) 2015-06-03
NO2605652T3 (enExample) 2018-04-07
EP3311666A1 (en) 2018-04-25
BR112013003631A8 (pt) 2017-12-26
HRP20210955T1 (hr) 2021-09-03
CN104672202B (zh) 2017-07-28
JP2017048192A (ja) 2017-03-09
PL3311666T3 (pl) 2021-11-08
US20200121663A1 (en) 2020-04-23
SI3311666T1 (sl) 2021-09-30
RU2016124136A (ru) 2018-12-03
US8629176B1 (en) 2014-01-14
PT3311666T (pt) 2021-06-21
BR112013003631A2 (pt) 2016-08-30
RS56855B1 (sr) 2018-04-30
RS62051B1 (sr) 2021-07-30
CA2807419C (en) 2019-09-24
CY1124466T1 (el) 2022-07-22
CY1120061T1 (el) 2018-12-12
CA2807419A1 (en) 2012-02-23
EP2605652A1 (en) 2013-06-26
SMT202100363T1 (it) 2021-07-12
DK2605652T3 (en) 2018-02-05
HUE036240T2 (hu) 2018-06-28
US8921413B2 (en) 2014-12-30
BR112013003631B1 (pt) 2021-10-13
LT3311666T (lt) 2021-07-12
ES2879314T3 (es) 2021-11-22
US20180333400A1 (en) 2018-11-22
JP2013535515A (ja) 2013-09-12
LT2605652T (lt) 2018-03-12
CN103153053A (zh) 2013-06-12
MX340997B (es) 2016-08-03
US20140080902A1 (en) 2014-03-20
HRP20180196T1 (hr) 2018-03-09
US20210353604A1 (en) 2021-11-18
MX354133B (es) 2018-02-14
US20150299157A1 (en) 2015-10-22
US20150299174A1 (en) 2015-10-22
HUE054810T2 (hu) 2021-09-28
DK3311666T3 (da) 2021-06-28
US10314832B2 (en) 2019-06-11
US8609717B2 (en) 2013-12-17
JP6407361B2 (ja) 2018-10-17
WO2012024404A1 (en) 2012-02-23
US9303010B2 (en) 2016-04-05
JP6162306B2 (ja) 2017-07-12
SMT201800065T1 (it) 2018-03-08
EP2605652A4 (en) 2014-02-19
EP3311666B1 (en) 2021-05-05
EP2605652B1 (en) 2017-11-08
PT2605652T (pt) 2018-01-08
PL2605652T3 (pl) 2018-04-30
AU2011291989B2 (en) 2015-08-20
EP3915367A1 (en) 2021-12-01
JP2017165773A (ja) 2017-09-21
US20120046320A1 (en) 2012-02-23
ES2652363T3 (es) 2018-02-01
MX2013001940A (es) 2013-06-28
RU2013111835A (ru) 2014-09-27
US9493437B2 (en) 2016-11-15

Similar Documents

Publication Publication Date Title
SI2605652T1 (en) Diketones and hydroxyketones as catenin signaling pathways
WO2014147021A3 (en) 3-acetylamino-1-(phenyl-heteroaryl-aminocarbonyl or phenyl-heteroaryl-carbonylamino)benzene derivatives for the treatment of hyperproliferative disorders
EP3456325A3 (en) Gamma-diketones as wnt/beta-catenin signalling pathway activators
BR112018000041A2 (pt) Derivados de carbamato de 1,1,1-trifluoro-3- hidroxipropan-2-ila e derivados de carbamato de 1,1,1-trifluoro-4-hidroxibutan-2-ila como inibidores de magl
RU2019131111A (ru) ПРОИЗВОДНОЕ ГЕТЕРОАРИЛ[4,3-с]ПИРИМИДИН-5-АМИНА, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО МЕДИЦИНСКИЕ ПРИМЕНЕНИЯ
PH12014502183A1 (en) Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
EA201500050A1 (ru) Бифтордиоксалан-амино-бензимидазольные ингибиторы киназы для лечения рака, аутоиммунного воспаления и нарушений цнс
CL2004000469A1 (es) Compuestos derivados de amidas del acido 1(h)-indol-2-carboxilico sustituido en posicion 7, acido benzo[b]tiofeno-2-carboxilico sustituido en posicion 7, y acido benzofurano-2-carboxilico sustituido en posicion 7; procedimiento de preparacion; compos
HK1223096A1 (zh) 用作par-2信號通路抑制劑的咪唑並噠嗪
JP2020502092A5 (enExample)
ME02390B (me) Inhibitori beta sekretaze
HRP20160553T1 (hr) Agonisti receptora neurotrofina i njihova uporaba kao lijekova
SI2875011T1 (en) 5-HT3 receptor antagonists
EA201500182A1 (ru) 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ
JP2013544277A5 (enExample)
GEP20166483B (en) Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament
RU2016151420A (ru) Новое терапевтическое применение производных бензилиденгуанидина для лечения протеинопатий
EA201792072A2 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
HRP20211277T1 (hr) Predlijek derivata aminokiseline
NI201000064A (es) MODULADORES DE PIPERIDINIL Y PIPERAZINIL DE LA y-SECRETASA.
HRP20140336T1 (hr) Inhibitori glicin transportera-1
IN2013DN02555A (enExample)
AR079103A1 (es) Compuesto de sal de mesilato de (s) -2-(4-(3-fluoro-benciloxi)-bencilamino)-propionamida, forma polimorfica (nf6) , composicion farmaceutica, uso del mismo para la preparacion de un medicamento y su procesos de preparacion
FR2974803B1 (fr) Procede de preparation d'un acide glycolique partiellement purifie
NI201000065A (es) CARBONO UNIDO A LOS MODULADORES DE LA y-SECRETASA.